Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Frequency Therapeutics participates in a conference call with JPMorgan » 09:23
10/19/20
10/19
09:23
10/19/20
09:23
FREQ

FREQ

/

+

SMid Cap Biotech Analyst…

SMid Cap Biotech Analyst Rama holds a conference call with CEO Lucchino on October 19 at 11 am hosted by JPMorgan.

ShowHide Related Items >><<
FREQ FREQ
/

+

FREQ FREQ
/

+

07/13/20 Oppenheimer
Frequency Therapeutics initiated with an Outperform at Oppenheimer
05/18/20 JPMorgan
JPMorgan downgrades Frequency Therapeutics on unclear data timelines
05/18/20 JPMorgan
Frequency Therapeutics downgraded to Neutral from Overweight at JPMorgan
10/28/19 JPMorgan
Frequency Therapeutics initiated with an Overweight at JPMorgan
FREQ FREQ
/

+

FREQ FREQ
/

+

FREQ FREQ
/

+

Conference/Events
Frequency Therapeutics management to meet virtually with Oppenheimer » 04:55
10/19/20
10/19
04:55
10/19/20
04:55
FREQ

FREQ

/

+

Virtual Meetings to be…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
FREQ FREQ
/

+

FREQ FREQ
/

+

07/13/20 Oppenheimer
Frequency Therapeutics initiated with an Outperform at Oppenheimer
05/18/20 JPMorgan
JPMorgan downgrades Frequency Therapeutics on unclear data timelines
05/18/20 JPMorgan
Frequency Therapeutics downgraded to Neutral from Overweight at JPMorgan
10/28/19 JPMorgan
Frequency Therapeutics initiated with an Overweight at JPMorgan
FREQ FREQ
/

+

FREQ FREQ
/

+

FREQ FREQ
/

+

Friday
Conference/Events
Frequency Therapeutics management to meet virtually with Oppenheimer » 10:40
10/16/20
10/16
10:40
10/16/20
10:40
FREQ

FREQ

/

+

Virtual Meetings to be…

Virtual Meetings to be held October 19-21 hosted by Oppenheimer.

ShowHide Related Items >><<
FREQ FREQ
/

+

FREQ FREQ
/

+

07/13/20 Oppenheimer
Frequency Therapeutics initiated with an Outperform at Oppenheimer
05/18/20 JPMorgan
JPMorgan downgrades Frequency Therapeutics on unclear data timelines
05/18/20 JPMorgan
Frequency Therapeutics downgraded to Neutral from Overweight at JPMorgan
10/28/19 JPMorgan
Frequency Therapeutics initiated with an Overweight at JPMorgan
FREQ FREQ
/

+

FREQ FREQ
/

+

FREQ FREQ
/

+

Over a week ago
Hot Stocks
Frequency Therapeutics completes patient enrollment of FX-322 » 07:32
09/22/20
09/22
07:32
09/22/20
07:32
FREQ

FREQ

/

+

Frequency Therapeutics…

Frequency Therapeutics announced the completion of enrollment of its Phase 2a study of FX-322 for sensorineural hearing loss, or SNHL. The company anticipates obtaining full results for the study, in which 95 patients were enrolled, in Q2 of 2021.

ShowHide Related Items >><<
FREQ FREQ
/

+

FREQ FREQ
/

+

07/13/20 Oppenheimer
Frequency Therapeutics initiated with an Outperform at Oppenheimer
05/18/20 JPMorgan
JPMorgan downgrades Frequency Therapeutics on unclear data timelines
05/18/20 JPMorgan
Frequency Therapeutics downgraded to Neutral from Overweight at JPMorgan
10/28/19 JPMorgan
Frequency Therapeutics initiated with an Overweight at JPMorgan
FREQ FREQ
/

+

  • 03
    Oct
FREQ FREQ
/

+

FREQ FREQ
/

+

Over a month ago
Hot Stocks
Frequency presents results from longer-term durability study of FX-322 » 15:24
09/13/20
09/13
15:24
09/13/20
15:24
FREQ

FREQ

/

+

Frequency Therapeutics…

Frequency Therapeutics presented clinical results from a longer-term durability study of FX-322, showing that some patients with chronic sensorineural hearing loss had significant improvement in key measures of hearing that were sustained for up to 21 months. These new data build upon Phase 1/2 study results previously detailed at the 2019 AAO-HNS conference that showed, for the first time, statistically significant improvements in word recognition scores in patients with chronic moderate to moderately severe SNHL. These patients had received a single intratympanic dose of FX-322 in a double-blind, placebo-controlled study, and had been evaluated for 90 days. Subsequent testing of a subset of these patients between 13 and 21 months after initial dosing, showed sustained improvements in measures of speech intelligibility (clarity), and in some patients, increased audibility threshold values at a higher frequency. Four of the patients that were observed to have statistically significant WR scores during the Phase 1/2 study had maintained those improvements in the follow up assessment. Three of these patients remained at statistically significant levels, maintaining an average increase of 87% in WR scores from their original baseline levels. The other patient maintained a 71% increase from their initial baseline, though that sustained improvement fell outside the range of statistical significance. An additional patient who did not achieve statistically significant change in WR during the Phase 1/2 study was also retested, and it was observed that their WR score had returned to baseline. Moreover, three of the patients that maintained statistically significant WR scores also showed 10-15dB improvements at 8000Hz compared to their original threshold values at this frequency. The safety profile observed in the FX-322 Phase 1/2 study was favorable and no additional safety findings were observed in the follow-up period. Together, these longer-term clinical data demonstrate the potential for FX-322 to have a durable positive impact both on measures of hearing clarity and volume.

ShowHide Related Items >><<
FREQ FREQ
/

+

FREQ FREQ
/

+

07/13/20 Oppenheimer
Frequency Therapeutics initiated with an Outperform at Oppenheimer
05/18/20 JPMorgan
JPMorgan downgrades Frequency Therapeutics on unclear data timelines
05/18/20 JPMorgan
Frequency Therapeutics downgraded to Neutral from Overweight at JPMorgan
10/28/19 JPMorgan
Frequency Therapeutics initiated with an Overweight at JPMorgan
FREQ FREQ
/

+

  • 03
    Oct
FREQ FREQ
/

+

FREQ FREQ
/

+

Syndicate
Frequency Therapeutics files to sell 2.35M shares of common stock for holders  16:18
08/28/20
08/28
16:18
08/28/20
16:18
FREQ

FREQ

/

+

 
ShowHide Related Items >><<
FREQ FREQ
/

+

FREQ FREQ
/

+

07/13/20 Oppenheimer
Frequency Therapeutics initiated with an Outperform at Oppenheimer
07/13/20 Oppenheimer
Frequency Therapeutics initiated with an Outperform at Oppenheimer
05/18/20 JPMorgan
JPMorgan downgrades Frequency Therapeutics on unclear data timelines
05/18/20 JPMorgan
JPMorgan downgrades Frequency Therapeutics on unclear data timelines
05/18/20 JPMorgan
Frequency Therapeutics downgraded to Neutral from Overweight at JPMorgan
05/18/20 JPMorgan
Frequency Therapeutics downgraded to Neutral from Overweight at JPMorgan
10/28/19 JPMorgan
Frequency Therapeutics initiated with an Overweight at JPMorgan
10/28/19 JPMorgan
Frequency Therapeutics initiated with an Overweight at JPMorgan
FREQ FREQ
/

+

  • 03
    Oct
  • 03
    Oct
FREQ FREQ
/

+

FREQ FREQ
/

+

Earnings
Frequency Therapeutics reports Q2 EPS (19c), consensus (18c) » 07:36
08/12/20
08/12
07:36
08/12/20
07:36
FREQ

FREQ

/

+

Reports Q2 revenue…

Reports Q2 revenue $8.52M, consensus $6.14M. "We are pleased with the steady progress in our Phase 2a study, despite the challenges of the pandemic, and we anticipate completing enrollment early in the fourth quarter of 2020 and sharing data from the study in the second quarter of 2021," said Frequency Therapeutics CEO David Lucchino. "In the last quarter, we generated compelling cochlear drug delivery data for FX-322, as well as important durability data suggesting that some patients who were given a single injection of FX-322 in our original Phase 1/2 study maintained statistically significant improvements in word recognition between 12 and 21 months following administration. We believe that these clinical advances are important building blocks as we work to further our understanding of FX-322 drug activity and the patient populations we hope to treat."

ShowHide Related Items >><<
FREQ FREQ
/

+

FREQ FREQ
/

+

07/13/20 Oppenheimer
Frequency Therapeutics initiated with an Outperform at Oppenheimer
05/18/20 JPMorgan
JPMorgan downgrades Frequency Therapeutics on unclear data timelines
05/18/20 JPMorgan
Frequency Therapeutics downgraded to Neutral from Overweight at JPMorgan
10/28/19 JPMorgan
Frequency Therapeutics initiated with an Overweight at JPMorgan
FREQ FREQ
/

+

  • 03
    Oct
FREQ FREQ
/

+

FREQ FREQ
/

+

Over a quarter ago
On The Fly
Fly Intel: After-Hours Movers » 18:58
07/13/20
07/13
18:58
07/13/20
18:58
INMB

INmune Bio

$8.74 /

+1.72 (+24.50%)

, VNDA

Vanda Pharmaceuticals

$11.37 /

-0.125 (-1.09%)

, FREQ

FREQ

/

+

, EW

Edwards Lifesciences

$67.18 /

-0.67 (-0.99%)

, BA

Boeing

$175.62 /

-2.825 (-1.58%)

, OSMT

Osmotica Pharmaceuticals

$7.71 /

-1.06 (-12.09%)

, ALT

Altimmune

$24.88 /

+2.56 (+11.47%)

Check out this evening's…

ShowHide Related Items >><<
VNDA Vanda Pharmaceuticals
$11.37 /

-0.125 (-1.09%)

OSMT Osmotica Pharmaceuticals
$7.71 /

-1.06 (-12.09%)

INMB INmune Bio
$8.74 /

+1.72 (+24.50%)

FREQ FREQ
/

+

EW Edwards Lifesciences
$67.18 /

-0.67 (-0.99%)

BA Boeing
$175.62 /

-2.825 (-1.58%)

ALT Altimmune
$24.88 /

+2.56 (+11.47%)

INMB INmune Bio
$8.74 /

+1.72 (+24.50%)

03/12/20 H.C. Wainwright
INmune Bio price target lowered to $8 from $11 at H.C. Wainwright
03/11/20 Roth Capital
INmune makes progress in all programs, novel COVID-19 approach,says Roth Capital
12/18/19 Roth Capital
INmune Bio initiated with a Buy at Roth Capital
08/21/19
Fly Intel: Top five analyst initiations
VNDA Vanda Pharmaceuticals
$11.37 /

-0.125 (-1.09%)

06/09/20 Citi
Vanda downgraded to Neutral on FDA dispute at Citi
06/09/20 Citi
Vanda Pharmaceuticals downgraded to Neutral from Buy at Citi
03/16/20
Fly Intel: Top five analyst downgrades
03/16/20 Oppenheimer
Vanda Pharmaceuticals downgraded to Underperform at Oppenheimer on Hetlioz risks
FREQ FREQ
/

+

07/13/20 Oppenheimer
Frequency Therapeutics initiated with an Outperform at Oppenheimer
05/18/20 JPMorgan
JPMorgan downgrades Frequency Therapeutics on unclear data timelines
05/18/20 JPMorgan
Frequency Therapeutics downgraded to Neutral from Overweight at JPMorgan
10/28/19 JPMorgan
Frequency Therapeutics initiated with an Overweight at JPMorgan
EW Edwards Lifesciences
$67.18 /

-0.67 (-0.99%)

06/05/20 Piper Sandler
Post points to Edwards resuming recruiting for CLASP trial, says Piper Sandler
04/28/20 Wells Fargo
Edwards Lifesciences downgraded on sales growth gap at Wells Fargo
04/28/20 Wells Fargo
Edwards Lifesciences downgraded to Equal Weight from Overweight at Wells Fargo
04/27/20 Barclays
Edwards Lifesciences price target lowered to $155 from $165 at Barclays
BA Boeing
$175.62 /

-2.825 (-1.58%)

07/09/20
Emirates tells Bloomberg Boeing 777X likely to miss 2021 debut
07/08/20 Bernstein
Bernstein downgrades Spirit AeroSystems on slower delivery recovery
06/26/20
Fly Intel: Top five analyst downgrades
06/26/20 RBC Capital
Spirit AeroSystems initiated with an Outperform at RBC Capital
OSMT Osmotica Pharmaceuticals
$7.71 /

-1.06 (-12.09%)

07/10/20 Truist
Osmotica Pharmaceuticals price target raised to $11 from $8 at SunTrust
07/09/20 RBC Capital
Osmotica price target raised to $12 from $10 at RBC Capital
03/23/20 Wells Fargo
Wells Fargo downgrades Osmotica to Equal Weight, halves price target to $4
03/23/20 Wells Fargo
Osmotica Pharmaceuticals downgraded to Equal Weight from Overweight at Wells Fargo
ALT Altimmune
$24.88 /

+2.56 (+11.47%)

06/01/20 Roth Capital
Altimmune surprises with differentiated T-COVID study, says Roth Capital
05/06/20 Roth Capital
Novo data 'sets up the runway' for Altimmune, says Roth Capital
04/01/20
Roth Capital biotech analyst to hold an analyst/industry conference call
VNDA Vanda Pharmaceuticals
$11.37 /

-0.125 (-1.09%)

OSMT Osmotica Pharmaceuticals
$7.71 /

-1.06 (-12.09%)

INMB INmune Bio
$8.74 /

+1.72 (+24.50%)

FREQ FREQ
/

+

EW Edwards Lifesciences
$67.18 /

-0.67 (-0.99%)

BA Boeing
$175.62 /

-2.825 (-1.58%)

ALT Altimmune
$24.88 /

+2.56 (+11.47%)

  • 14
    Jul
  • 14
    Jul
  • 09
    Jan
  • 03
    Oct
EW Edwards Lifesciences
$67.18 /

-0.67 (-0.99%)

BA Boeing
$175.62 /

-2.825 (-1.58%)

VNDA Vanda Pharmaceuticals
$11.37 /

-0.125 (-1.09%)

OSMT Osmotica Pharmaceuticals
$7.71 /

-1.06 (-12.09%)

EW Edwards Lifesciences
$67.18 /

-0.67 (-0.99%)

BA Boeing
$175.62 /

-2.825 (-1.58%)

ALT Altimmune
$24.88 /

+2.56 (+11.47%)

FREQ FREQ
/

+

BA Boeing
$175.62 /

-2.825 (-1.58%)

ALT Altimmune
$24.88 /

+2.56 (+11.47%)

Initiation
Frequency Therapeutics initiated with an Outperform at Oppenheimer » 16:10
07/13/20
07/13
16:10
07/13/20
16:10
FREQ

FREQ

/

+

Oppenheimer analyst Jay…

Oppenheimer analyst Jay Olson initiated coverage of Frequency Therapeutics with an Outperform rating and $36 price target. The analyst said that, given the substantial market opportunity and limited treatment options available, he believes Frequency's FX-322 holds the promise to "revolutionize" the treatment of hearing loss.

ShowHide Related Items >><<
FREQ FREQ
/

+

FREQ FREQ
/

+

05/18/20 JPMorgan
JPMorgan downgrades Frequency Therapeutics on unclear data timelines
05/18/20 JPMorgan
Frequency Therapeutics downgraded to Neutral from Overweight at JPMorgan
10/28/19 JPMorgan
Frequency Therapeutics initiated with an Overweight at JPMorgan
10/28/19 Cowen
Frequency Therapeutics initiated with an Outperform at Cowen
FREQ FREQ
/

+

  • 03
    Oct
FREQ FREQ
/

+

Conference/Events
Healthcare Financial Management Association to hold a virtual conference » 08:56
06/24/20
06/24
08:56
06/24/20
08:56
MTBC

MTBC

$8.50 /

-0.26 (-2.97%)

, NVZMY

Novozymes

$0.00 /

+ (+0.00%)

, NVS

Novartis

$90.49 /

-0.09 (-0.10%)

, NVAX

Novavax

$69.66 /

+3.72 (+5.64%)

, MRK

Merck

$77.11 /

+0.4 (+0.52%)

, LOGI

Logitech

$62.73 /

-0.32 (-0.51%)

, REGN

Regeneron

$628.72 /

+0.81 (+0.13%)

, RDY

Dr. Reddy's

$54.33 /

+1.04 (+1.95%)

, FREQ

FREQ

/

+

, RCKT

Rocket Pharmaceuticals

$22.80 /

+0.275 (+1.22%)

, TRVI

Trevi Therapeutics

$5.71 /

+0.26 (+4.77%)

, CSU

Capital Senior Living

$0.76 /

-0.037 (-4.64%)

, NVO

Novo Nordisk

$67.93 /

-0.005 (-0.01%)

HFMA 2020 Digital Annual…

HFMA 2020 Digital Annual Conference will be held on June 24. Webcast Link

ShowHide Related Items >><<
TRVI Trevi Therapeutics
$5.71 /

+0.26 (+4.77%)

REGN Regeneron
$628.72 /

+0.81 (+0.13%)

RDY Dr. Reddy's
$54.33 /

+1.04 (+1.95%)

RCKT Rocket Pharmaceuticals
$22.80 /

+0.275 (+1.22%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

NVO Novo Nordisk
$67.93 /

-0.005 (-0.01%)

NVAX Novavax
$69.66 /

+3.72 (+5.64%)

MTBC MTBC
$8.50 /

-0.26 (-2.97%)

MRK Merck
$77.11 /

+0.4 (+0.52%)

LOGI Logitech
$62.73 /

-0.32 (-0.51%)

FREQ FREQ
/

+

CSU Capital Senior Living
$0.76 /

-0.037 (-4.64%)

MTBC MTBC
$8.50 /

-0.26 (-2.97%)

06/22/20 H.C. Wainwright
MTBC upgraded to Buy from Neutral at H.C. Wainwright
06/02/20 Ladenburg
MTBC initiated with a Buy at Ladenburg
03/03/20
LD Micro to hold a virtual conference
03/02/20
Fly Intel: Top five analyst downgrades
03/02/20 H.C. Wainwright
MTBC downgraded to Neutral from Buy at H.C. Wainwright
NVZMY Novozymes
$0.00 /

+ (+0.00%)

05/12/20 Credit Suisse
Novozymes downgraded to Underperform from Outperform at Credit Suisse
04/01/20 Goldman Sachs
Novozymes downgraded to Sell from Buy at Goldman Sachs
03/13/20
Goldman Sachs to hold a conference
01/14/20 Exane BNP Paribas
Novozymes downgraded to Neutral from Outperform at Exane BNP Paribas
NVS Novartis
$90.49 /

-0.09 (-0.10%)

06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
06/16/20 Guggenheim
Guggenheim upgrades Alcon to Buy on strong momentum exiting shutdown
06/15/20
Fly Intel: Top five analyst upgrades
06/15/20 Citi
Novartis upgraded to Buy from Neutral at Citi
NVAX Novavax
$69.66 /

+3.72 (+5.64%)

06/19/20 Cantor Fitzgerald
Novavax price target raised to $88 from $45 at Cantor Fitzgerald
06/05/20
Fly Intel: Top five analyst upgrades
06/05/20 JPMorgan
JPMorgan upgrades Novavax to Neutral despite 'shaky fundamentals'
06/05/20 B. Riley Securities
Novavax price target raised to $74 from $61 at B. Riley FBR
MRK Merck
$77.11 /

+0.4 (+0.52%)

06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/23/20 Morgan Stanley
Merck's COVID-19 antiviral candidate underappreciated, says Morgan Stanley
06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
06/12/20 Wolfe Research
Merck downgraded to Peer Perform from Outperform at Wolfe Research
LOGI Logitech
$62.73 /

-0.32 (-0.51%)

06/24/20 Wedbush
Logitech downgraded to Neutral at Wedbush with limited multiple expansion ahead
06/24/20 Wedbush
Logitech downgraded to Neutral from Outperform at Wedbush
06/04/20 DA Davidson
Logitech price target raised to $70 from $64 at DA Davidson
05/21/20
Fly Intel: Top five analyst downgrades
REGN Regeneron
$628.72 /

+0.81 (+0.13%)

06/24/20 Credit Suisse
Regeneron price target raised to $700 from $605 at Credit Suisse
06/18/20 Piper Sandler
AbbVie atopic dermatitis data a postive, says Piper Sandler
06/15/20 Piper Sandler
Piper says 'meaningfully above-consensus estimates' for Dupixent are right
RDY Dr. Reddy's
$54.33 /

+1.04 (+1.95%)

06/17/20 SVB Leerink
Amarin doubling down on appeal after settlement with Apotex, says SVB Leerink
06/17/20 Stifel
Amarin settlement with Apotex an 'incremental positive,' says Stifel
04/21/20 Nomura
Dr. Reddy's price target raised to INR 4,426 from INR 3,684
03/31/20 Goldman Sachs
Goldman downgrades Amarin, cuts target to $4 from $27 after patent ruling
FREQ FREQ
/

+

05/18/20 JPMorgan
JPMorgan downgrades Frequency Therapeutics on unclear data timelines
05/18/20 JPMorgan
Frequency Therapeutics downgraded to Neutral from Overweight at JPMorgan
10/28/19 JPMorgan
Frequency Therapeutics initiated with an Overweight at JPMorgan
10/28/19 Cowen
Frequency Therapeutics initiated with an Outperform at Cowen
RCKT Rocket Pharmaceuticals
$22.80 /

+0.275 (+1.22%)

05/13/20 Piper Sandler
Rocket Pharmaceuticals programs look even more promising, says Piper Sandler
03/05/20 Piper Sandler
Piper sees 'substantial value' for Rocket from numerous trial readouts
12/09/19 Oppenheimer
Rocket Pharmaceuticals price target raised to $42 from $36 at Oppenheimer
12/06/19 Baird
Rocket Pharmaceuticals elevated to Fresh Pick, target raised to $41 at Baird
TRVI Trevi Therapeutics
$5.71 /

+0.26 (+4.77%)

CSU Capital Senior Living
$0.76 /

-0.037 (-4.64%)

09/03/19 Barclays
Capital Senior Living initiated with an Underweight at Barclays
NVO Novo Nordisk
$67.93 /

-0.005 (-0.01%)

06/05/20 JPMorgan
JPMorgan backs Overweight on Novo Nordisk after STEP data
05/18/20 Morgan Stanley
Novo Nordisk price target raised to DKK 435 from DKK 425 at Morgan Stanley
05/13/20 JPMorgan
Novo Nordisk price target raised to DKK 480 from DKK 460 at JPMorgan
05/11/20
Fly Intel: Top five analyst downgrades
TRVI Trevi Therapeutics
$5.71 /

+0.26 (+4.77%)

REGN Regeneron
$628.72 /

+0.81 (+0.13%)

RDY Dr. Reddy's
$54.33 /

+1.04 (+1.95%)

RCKT Rocket Pharmaceuticals
$22.80 /

+0.275 (+1.22%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

NVO Novo Nordisk
$67.93 /

-0.005 (-0.01%)

NVAX Novavax
$69.66 /

+3.72 (+5.64%)

MTBC MTBC
$8.50 /

-0.26 (-2.97%)

MRK Merck
$77.11 /

+0.4 (+0.52%)

LOGI Logitech
$62.73 /

-0.32 (-0.51%)

FREQ FREQ
/

+

CSU Capital Senior Living
$0.76 /

-0.037 (-4.64%)

REGN Regeneron
$628.72 /

+0.81 (+0.13%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

NVO Novo Nordisk
$67.93 /

-0.005 (-0.01%)

NVAX Novavax
$69.66 /

+3.72 (+5.64%)

MRK Merck
$77.11 /

+0.4 (+0.52%)

REGN Regeneron
$628.72 /

+0.81 (+0.13%)

RDY Dr. Reddy's
$54.33 /

+1.04 (+1.95%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

NVO Novo Nordisk
$67.93 /

-0.005 (-0.01%)

NVAX Novavax
$69.66 /

+3.72 (+5.64%)

MRK Merck
$77.11 /

+0.4 (+0.52%)

LOGI Logitech
$62.73 /

-0.32 (-0.51%)

REGN Regeneron
$628.72 /

+0.81 (+0.13%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

NVAX Novavax
$69.66 /

+3.72 (+5.64%)

MRK Merck
$77.11 /

+0.4 (+0.52%)

LOGI Logitech
$62.73 /

-0.32 (-0.51%)

FREQ FREQ
/

+

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.